Prespecified Subgroup Analyses of Ocrelizumab Efficacy in Patients With Primary Progressive Multiple Sclerosis From the Phase III ORATORIO Study

JS Wolinsky,1 X Montalban,2,3 X Sl Hauser,1 L Kappos,4 L Julian,5 M Manfrini,5 S Belachew,6 F Model,6 S Hubeaux,6 A Bar-On7

1McGill Medical School, UHealth, Houston, TX, USA; 2Division of Neurology, University of Toronto, Toronto, ON, Canada; 3Hôpital Necker University Hospital, Barcelona, Spain; 4University of California, San Francisco, San Francisco, CA, USA; 5University Hospital Basel, University of Basel, Basel, Switzerland; 6Genentech, Inc., South San Francisco, CA, USA; 7F. Hoffmann-La Roche Ltd, Basel, Switzerland; 8University of Pennsylvania, Philadelphia, PA, USA

ACKNOWLEDGMENTS

Financial disclosures: J. Wolinsky is on the Speakers Bureau for Biogen and Novartis; JS Wolinsky, X. Montalban, X. Sl Hauser, L. Kappos, L. Julian, M. Manfrini, S. Belachew, F. Model, S. Hubeaux, A. Bar-On are employees of Genentech, Inc., and are shareholders of F. Hoffmann-La Roche Ltd. M. Manfrini is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd. JS Wolinsky, X. Montalban, X. Sl Hauser, L. Kappos, L. Julian, M. Manfrini, S. Belachew, F. Model, S. Hubeaux, A. Bar-On have served as consultants or received research support from Biogen, Merck, Novartis, and Sanofi Genzyme.

REFERENCES

Presented at the 2018 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC); May 30–June 2, 2018; Nashville, TN, USA

Poster D42